The pharmaceutical company WERTEKS has summarized its preliminary operational results for 2025 (final financial results will be published later). According to estimates as of early March 2026, the manufacturer’s revenue grew by almost 14% compared to 2024 and exceeded 24.9 billion rubles (excluding VAT).
Financial Indicators and Investments
Based on revenue volume for 2025, WERTEKS entered the top 3 companies among the 67 residents of the “St. Petersburg” Special Economic Zone (SEZ).
- The volume of tax and other deductions by the manufacturer in 2025 amounted to approximately 3.37 billion rubles;
- The volume of investments in the “St. Petersburg” SEZ territory exceeded 420 million rubles last year;
- The company’s total investments since the beginning of the construction of the innovation and production complex (with an area of over 56.5 thousand sq. m) in 2013 have surpassed the 13 billion ruble mark.
“The company continues to implement projects to ensure production stability and maintain product availability for consumers. They are aimed at increasing productivity, reducing the labor intensity of technological processes, and lowering the cost of goods.”
— Georgy Pobelyansky, General Director of WERTEKS Pharmaceutical Company
Sales Structure and Demand Leaders
Traditionally, medicines form the core of the company’s sales—in 2025, they accounted for 90% of the total sales volume. Of these, vital and essential drugs (VED) make up more than 74% in physical terms and 61% in monetary terms.
According to the marketing agency DSM Group, WERTEKS ranked first in the number of presented items (SKUs) among St. Petersburg pharmaceutical manufacturers in the retail pharmacy segment.
The company’s most sought-after products in Russian pharmacies (according to DSM Group):
- Medicines: a drug with the active ingredient bisoprolol (used to treat cardiovascular diseases, included in the VED list);
- Cosmetics: “Asepta®” adhesive gum balm;
- Dietary Supplements: “ALERANA®” vitamin and mineral complex.
Export Direction
In 2025, a new direction was added to the export pool of CIS countries: WERTEKS entered the Asian market, making its first product deliveries to Laos. The shipment assortment included original combination and generic drugs, as well as cosmetic products.
Summary of 2025 Results
| Indicator | Value |
|---|---|
| Revenue (excluding VAT) | > 24.9 billion rubles (+14% vs. 2024) |
| Tax Deductions | ~ 3.37 billion rubles |
| Production Investments (2025) | > 420 million rubles |
| Share of Medicines in Sales Volume | 90% |
| Share of VED (in physical terms) | > 74% |
| New Export Markets | Laos |
